Clinical Trial Update: BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A two-phase clinical trial evaluating BYL719 (alpelisib) with nab-paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BYL719 (alpelisib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Priyanka Sharma | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-28